MIRATI THERAPEUTICS INC's ticker is MRTX and the CUSIP is 60468T105. A total of 228 filers reported holding MIRATI THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 1.34 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $38,932,316 | +23.3% | 893,763 | +2.3% | 0.28% | +21.1% |
| Q2 2023 | $31,569,057 | +20.7% | 873,763 | +14.3% | 0.23% | +26.0% |
| Q1 2023 | $26,154,414 | -24.8% | 764,265 | -0.4% | 0.18% | -23.0% |
| Q4 2022 | $34,778,146 | -24.8% | 767,596 | +15.9% | 0.24% | -27.9% |
| Q3 2022 | $46,271,000 | +16.0% | 662,501 | +11.5% | 0.33% | -0.9% |
| Q2 2022 | $39,893,000 | -4.3% | 594,284 | +17.3% | 0.33% | +15.8% |
| Q1 2022 | $41,665,000 | -42.3% | 506,773 | +2.9% | 0.28% | -38.4% |
| Q4 2021 | $72,242,000 | +6.6% | 492,483 | +28.5% | 0.46% | 0.0% |
| Q3 2021 | $67,793,000 | +21.4% | 383,219 | +10.9% | 0.46% | +20.7% |
| Q2 2021 | $55,824,000 | +39.9% | 345,596 | +82.8% | 0.38% | +15.1% |
| Q1 2021 | $39,896,000 | -3.9% | 189,100 | +0.0% | 0.33% | +0.9% |
| Q4 2020 | $41,536,000 | +87.9% | 189,098 | +42.0% | 0.33% | +58.2% |
| Q3 2020 | $22,107,000 | +75.9% | 133,137 | +21.0% | 0.21% | +56.4% |
| Q2 2020 | $12,566,000 | +0.4% | 110,061 | +10.8% | 0.13% | -4.3% |
| Q1 2020 | $12,511,000 | -2.3% | 99,328 | +0.0% | 0.14% | +1.5% |
| Q4 2019 | $12,799,000 | +34.3% | 99,323 | -18.8% | 0.14% | +8.7% |
| Q3 2019 | $9,528,000 | -40.8% | 122,300 | -22.1% | 0.13% | -37.3% |
| Q2 2019 | $16,100,000 | +94.4% | 157,000 | +38.9% | 0.20% | +89.6% |
| Q1 2019 | $8,283,000 | -7.5% | 113,000 | -46.4% | 0.11% | -23.2% |
| Q4 2018 | $8,950,000 | -1.0% | 211,000 | +9.9% | 0.14% | +15.0% |
| Q3 2018 | $9,043,000 | +97.9% | 192,000 | +107.1% | 0.12% | +66.7% |
| Q2 2018 | $4,570,000 | +1096.3% | 92,700 | +32.4% | 0.07% | +620.0% |
| Q2 2016 | $382,000 | -82.7% | 70,000 | -32.7% | 0.01% | -81.8% |
| Q1 2016 | $2,214,000 | -39.1% | 104,000 | -9.6% | 0.06% | -43.3% |
| Q4 2015 | $3,634,000 | -1.3% | 115,000 | +7.5% | 0.10% | +7.8% |
| Q3 2015 | $3,683,000 | +6.4% | 107,000 | -2.7% | 0.09% | +25.0% |
| Q2 2015 | $3,462,000 | +3.6% | 110,000 | -3.5% | 0.07% | +7.5% |
| Q1 2015 | $3,343,000 | +157.9% | 114,000 | +62.9% | 0.07% | +148.1% |
| Q4 2014 | $1,296,000 | – | 70,000 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aviva Holdings Ltd. | 3,135,966 | $136,602,679 | 87.83% |
| EcoR1 Capital, LLC | 5,748,399 | $250,400,260 | 8.45% |
| Boxer Capital, LLC | 3,201,440 | $139,454,726 | 7.42% |
| RTW INVESTMENTS, LP | 6,768,514 | $294,836,470 | 6.22% |
| Paradigm Biocapital Advisors LP | 1,668,116 | $72,663,133 | 4.93% |
| Avoro Capital Advisors LLC | 6,666,666 | $290,399,971 | 4.53% |
| Octagon Capital Advisors LP | 655,051 | $28,534,022 | 4.38% |
| Artal Group S.A. | 2,024,226 | $88,175 | 3.78% |
| Ally Bridge Group (NY) LLC | 70,283 | $3,061,527 | 3.59% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 216,000 | $9,404,640 | 3.17% |